Recent findings suggest that monotherapy with anti-LAG-3 or its combination with anti-PD-1 shows promise for patients with LAG-3+ ccRCC who are refractory to anti-PD-1 therapy. This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.